Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors

Summary

This is an open-label, multi-center, dose-escalation Phase I study to evaluate safety, pharmacokinetics and activity of CH5132799 administered orally as a single agent in patients with advanced solid tumors.

Timeline

Start

2010-08

Primary completion

2012-11

Completion

2012-12

Drugs

Indications